IP Library Granted Patent US 8,476,013
Granted Patent B2
US 8,476,013 · App. 12/561,241 · Granted Jul 2, 2013

Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses

Inventors: Mathias Ehrich (San Diego, CA); Anders Olof Herman Nygren (San Diego, CA)
Assignee: Sequenom, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,476,013
App. No.
12/561,241
Granted
Jul 2, 2013
Kind
B2
Abstract

Provided are compositions and processes that utilize genomic regions differentially methylated between a mother and her fetus to separate, isolate or enrich fetal nucleic acid from a maternal sample. The compositions and processes described herein are useful for non-invasive prenatal diagnostics, including the detection of chromosomal aneuplodies.

Claims (24)

1. A method for determining the presence or absence of a fetal aneuploidy comprising:

a) digesting nucleic acid from a pregnant female, which nucleic acid comprises fetal nucleic acid and maternal nucleic acid, with a methylation sensitive restriction enzyme that specifically digests non-methylated maternal nucleic acid at a plurality of loci, wherein the plurality of loci comprises the locus of SEQ ID NO:38, thereby enriching the fetal nucleic acid;

b) determining the amount of fetal nucleic acid from a target chromosome;

c) determining the amount of fetal nucleic acid from a reference chromosome and;

d) comparing the amount of fetal nucleic acid determined in step (b) to the amount of fetal nucleic acid determined in step (c), whereby a statistically significant difference between the amount of fetal nucleic acid determined in step (b) and the amount of fetal nucleic acid determined in step (c) determines the presence of a fetal aneuploidy.

2. The method of claim 1 , wherein the amount of fetal nucleic acid at between 3 and 15 loci on each of the target chromosome and reference chromosome is determined.

3. The method of claim 1 , wherein the digestion efficiency of the methylation sensitive restriction enzyme is determined.

4. The method of claim 1 , wherein determining the amount of fetal nucleic acid in (b) and/or (c) comprises use of a competitor-based amplification method.

5. The method of claim 1 , wherein the method further comprises determining the presence or absence of Y-chromosome nucleic acid present in the nucleic acid.

6. The method of claim 5 , wherein the amount of Y-chromosome nucleic acid present in the nucleic acid is determined for a male fetus.

7. The method of claim 6 , wherein the amount of fetal nucleic acid is compared to the amount of Y-chromosome nucleic acid.

8. The method of claim 1 , wherein the total amount of nucleic acid is determined.

9. The method of claim 1 , wherein the total amount of nucleic acid and the amount of Y-chromosome nucleic acid for a male fetus are determined.

10. The method of claim 1 , wherein the total amount of nucleic acid, the amount of Y-chromosome nucleic acid for a male fetus, and the digestion efficiency of the methylation sensitive restriction enzyme are determined.

11. The method of claim 10 , wherein two or more assays are used to determine the total amount of nucleic acid, one or more assays are used to determine the amount of Y-chromosome nucleic acid for a male fetus, and one or more assays are used to determine the digestion efficiency of the methylation sensitive restriction enzyme.

12. The method of claim 11 , wherein the amount of fetal nucleic acid at 3 or more loci is determined.

13. The method of claim 1 , wherein the amount of fetal nucleic acid is determined by an amplification reaction that generates amplicons larger than the average length of the digested maternal nucleic acid, thereby further enriching the fetal nucleic acid.

14. The method of claim 1 , wherein determining the amount of fetal nucleic acid in (b) and/or (c) comprises use of a mass spectrometry method.

15. The method of claim 1 , wherein determining the amount of fetal nucleic acid in (b) and/or (c) comprises use of a sequencing method.

16. The method of claim 15 , wherein the sequencing method comprises sequencing by synthesis.

17. The method of claim 1 , wherein the plurality of loci further comprises one or more loci selected from loci of SEQ ID NOs:1 to 37 and SEQ ID NOs:39 to 59.

18. The method of claim 1 , wherein the plurality of loci further comprises one or more loci selected from loci of SEQ ID NOs:1 to 37 and SEQ ID NO:39.

19. The method of claim 1 , wherein the plurality of loci further comprises one or more loci selected from loci of SEQ ID NOs:33, 34, 35, 36, 37, and 39.

20. The method of claim 1 , wherein the amount of fetal nucleic acid at about 16 or more loci on each of the target chromosome and reference chromosome is determined.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2016
From: SEQUENOM CENTER FOR MOLECULAR MEDICINE, LLC
To: SEQUENOM, INC.
Reel/Frame 039557/0090 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2010
From: EHRICH, MATHIAS
To: SEQUENOM, INC.
Reel/Frame 025507/0224 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2010
From: NYGREN, ANDERS OLOF HERMAN
To: SEQUENOM CENTER FOR MOLECULAR MEDICINE
Reel/Frame 025507/0329 →
Continuity (2)
Provisional Application 61192264 · Sep 16, 2008
Related Publication 20100105049A1 · Apr 29, 2010